ServiceNow Inc vs GeneDx Holdings Corp — how do they compare? ServiceNow Inc trades at $124.72 (market cap $131.86B), while GeneDx Holdings Corp trades at $82.5 (market cap $2.44B). The key difference: ServiceNow Inc is far larger — about 54× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| NOW | WGS | |
|---|---|---|
Market Cap | $131.86B | $2.44B |
Sector | Technology | Technology |
52-Week High | $192.23 | $167.51 |
52-Week Low | $83.00 | $34.51 |
Enterprise Value | $135.65B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $127.44, up 2.05% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. Revenue grew to $13.28B in 2025, with a net income margin of 11.34%, though high P/E of 79.71 indicates premium valuation. Recent news highlights AI-driven growth opportunities, including partnerships and conference presentations in June 2026.
The stock offers growth potential from AI adoption and strong cash flows, but faces risks from elevated valuations and competitive pressures. Analyst consensus is strongly bullish with an average price target of $138.26, though investors should monitor earnings consistency and macroeconomic headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →